MK-6482-011

MK-6482-011 : An open-label, randomized, Phase 3 Study of MK-6482 in combination with Lenvatinib (MK-7902) vs Cabozantinib for second-line or third-line treatment in participants with advanced renal cell carcinoma who have progressed after prior Anti-PD-1/L1 therapy

Weitere Informationen finden Sie hier